Compare AJANTA PHARMA with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA SANOFI INDIA AJANTA PHARMA/
SANOFI INDIA
 
P/E (TTM) x 27.3 42.9 63.7% View Chart
P/BV x 6.7 8.7 77.2% View Chart
Dividend Yield % 0.5 1.0 52.4%  

Financials

 AJANTA PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
SANOFI INDIA
Dec-18
AJANTA PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,4226,840 20.8%   
Low Rs8984,630 19.4%   
Sales per share (Unadj.) Rs233.51,203.1 19.4%  
Earnings per share (Unadj.) Rs44.0165.3 26.6%  
Cash flow per share (Unadj.) Rs52.2209.9 24.9%  
Dividends per share (Unadj.) Rs9.0084.00 10.7%  
Dividend yield (eoy) %0.81.5 53.0%  
Book value per share (Unadj.) Rs255.1963.6 26.5%  
Shares outstanding (eoy) m88.0223.03 382.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.04.8 104.2%   
Avg P/E ratio x26.434.7 76.0%  
P/CF ratio (eoy) x22.227.3 81.4%  
Price / Book Value ratio x4.56.0 76.4%  
Dividend payout %20.550.8 40.3%   
Avg Mkt Cap Rs m102,081132,078 77.3%   
No. of employees `0006.83.3 206.0%   
Total wages/salary Rs m4,3074,068 105.9%   
Avg. sales/employee Rs Th3,022.68,393.8 36.0%   
Avg. wages/employee Rs Th633.41,232.4 51.4%   
Avg. net profit/employee Rs Th569.11,153.0 49.4%   
INCOME DATA
Net Sales Rs m20,55427,708 74.2%  
Other income Rs m211897 23.5%   
Total revenues Rs m20,76528,605 72.6%   
Gross profit Rs m5,6646,235 90.8%  
Depreciation Rs m7211,027 70.2%   
Interest Rs m127 165.7%   
Profit before tax Rs m5,1436,098 84.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2732,292 55.5%   
Profit after tax Rs m3,8703,806 101.7%  
Gross profit margin %27.622.5 122.5%  
Effective tax rate %24.837.6 65.9%   
Net profit margin %18.813.7 137.1%  
BALANCE SHEET DATA
Current assets Rs m11,81215,922 74.2%   
Current liabilities Rs m3,7766,235 60.6%   
Net working cap to sales %39.135.0 111.8%  
Current ratio x3.12.6 122.5%  
Inventory Days Days7764 121.6%  
Debtors Days Days8221 391.0%  
Net fixed assets Rs m14,3987,539 191.0%   
Share capital Rs m175230 76.3%   
"Free" reserves Rs m22,27721,962 101.4%   
Net worth Rs m22,45222,192 101.2%   
Long term debt Rs m70-   
Total assets Rs m26,96229,839 90.4%  
Interest coverage x444.3872.1 50.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.9 82.1%   
Return on assets %14.412.8 112.7%  
Return on equity %17.217.2 100.5%  
Return on capital %23.027.5 83.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,6827,587 140.8%   
Fx outflow Rs m2,1027,145 29.4%   
Net fx Rs m8,580442 1,941.1%   
CASH FLOW
From Operations Rs m3,7483,739 100.2%  
From Investments Rs m-2,228-731 304.8%  
From Financial Activity Rs m-1,475-1,972 74.8%  
Net Cashflow Rs m451,036 4.4%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 1.6 14.4 10.8%  
FIIs % 7.6 14.6 52.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.5 161.9%  
Shareholders   20,968 15,184 138.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   IPCA LABS  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Crucial Week Ahead for the Indian Stock Market(Momentum Moves)

The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 22, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - DISHMAN PHARMA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS